Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intarcia

- PMLiVE

AstraZeneca and its diabetes plans

Director of marketing Chris Boulton is bullish on its prospects

- PMLiVE

AZ and Inserm collaborate on diabetes and kidney disease

Three-year partnership will look at new therapeutic approaches

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

Bayer sells diabetes division to Panasonic Healthcare

€1.02bn sale includes Contour electronic meters and other medical devices

- PMLiVE

Sanofi will resubmit Lyxumia for FDA approval in Q3

Follows the GLP-1 agonist's all-clear by ELIXA cardiovascular safety study

- PMLiVE

Merck & Co’s diabetes drug Januvia cleared by CV safety trial

Concerns over the DPP-4 inhibitor 'put to bed' by TECOS cardiovascular trial

- PMLiVE

Rivals look to put pressure on Sanofi’s Lantus

Novo Nordisk and Lilly claim clinical benefitsover top-selling diabetes drug

- PMLiVE

Novo brings Xultophy to third European market

Launches diabetes combination of Tresiba-Victoza in the UK

- PMLiVE

FDA gives priority review for Keytruda in lung cancer

The regulator is expected to deliver a verdict by October 2 

- PMLiVE

Amgen and Merck to expand cancer collaboration

Firms to test Keytruda in combination for cancers inside the head and neck

Bristol-Myers Squibb (BMS) building

BMS melanoma combo impresses at ASCO

Increases survival in difficult to treat form of skin cancer

- PMLiVE

Merck files all-oral hepatitis C therapy in US

Seeking approval for grazoprevir and elbasvir, which already has FDA breakthrough status

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links